GlobeNewswire Inc | Aug 23, 2021 07:31AM EDT

August 23, 2021

BOTHELL, Wash., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Chief Medical Officer, Hans Moebius, will present on the application of clinically established Evoked-Response Potentials (ERPs) by using ERP P300 in Alzheimers drug development, and the utility of ERP P300 in Athiras Phase 1 clinical trials, at the Annual Biomarkers for Alzheimers Disease Summit taking place virtually August 24-26, 2021.

Presentation Details

Title:Advances in Direct, Functional, Non-Invasive Biomarkers; Athiras Utilization of ERP P300Presenter: Hans J. Moebius, MD, PhD, Chief Medical Officer, Athira Pharma, Inc.Date: Wednesday, August 25, 2021Time: 12:10 p.m. PT / 3:10 p.m. ET

About Athira Pharma, Inc.Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimers and Parkinsons dementia. For more information, visitwww.athira.com. You can also follow Athira onFacebook,LinkedInand@athirapharma onTwitterandInstagram.

Investor & Media Contact:Julie RathbunAthira Pharma, Inc.Julie.rathbun@athira.com206-769-9219